MedTrace Logo

AZD7268 Safety and Tolerability Study

NCT01020799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 247

Last updated 2012-04-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.

Conditions

Interventions

DRUG

AZD7268

15 mg, oral, twice daily (BID)

DRUG

Escitalopram

20 mg, oral, once daily (QD)

DRUG

Placebo capsules

Placebo capsules to match AZD7268

DRUG

Placebo tablets

Placebo tablets to match encapsulated escitalopram

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020799 on ClinicalTrials.gov